Patents by Inventor Daniel Jon Sall

Daniel Jon Sall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20110263602
    Abstract: The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C—R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or trifluoromethyl; R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; R5 is trifluoromethyl or methylsulfonyl; R6 is hydrogen or methyl; and R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R7, R8, R9, R10 and R11 are hydrogen useful in the treatment of cancer.
    Type: Application
    Filed: November 5, 2009
    Publication date: October 27, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Jeffrey Daniel Cohen, Philip Arthur Hipskind, Karen Lynn Lobb, Daniel Jon Sall, Michelle Lee Thompson, Takako Wilson (nee Takakuwa)
  • DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20110190304
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Application
    Filed: October 22, 2009
    Publication date: August 4, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jolie Anne Bastian, Philip Arthur Hipskind, Daniel Jon Sall, Takako Wilson (nee Takakuwa)
  • TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20110178093
    Abstract: The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Application
    Filed: November 9, 2009
    Publication date: July 21, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Takako Wilson (nee Takakuwa), Michelle Lee Thompson, Daniel Jon Sall, Philip Arthur Hipskind
  • Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders
    Patent number: 7297706
    Abstract: Compounds of formula (I) in which R, R1, R2, n and X1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.
    Type: Grant
    Filed: July 11, 2006
    Date of Patent: November 20, 2007
    Assignee: Eli Lilly and Company
    Inventors: Michael Robert Wiley, Daniel Jon Sall, Christopher William Murray, Stephen Clinton Young, Jolie Anne Bastian
  • Chemical compounds
    Patent number: 7294627
    Abstract: Compounds of formula (I) in which R1, R2, R3 and R4, have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: November 13, 2007
    Assignee: Eli Lilly and Company
    Inventors: Steven Douglas Hiscock, Stuart Donald Jones, Daniel Jon Sall, Stephen Clinton Young, Michael Robert Wiley
  • ?adrenergic agonists
    Patent number: 7265127
    Abstract: The present invention relates to 2-imidazo[1,2-a]pyridine group containing ?3 adrenergic receptor agonists or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: September 4, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • Chemical compounds
    Patent number: 7265121
    Abstract: Compounds of formula (I) in which R1, R2 and X4 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: September 4, 2007
    Assignee: Eli Lilly and Company
    Inventors: Michael Robert Wiley, Daniel Jon Sall, John Walter Liebeschuetz
  • ?adrenergic agonists
    Patent number: 7253181
    Abstract: The present invention relates to pyrrolopyridine-3-yl group containing ?3 adrenergic receptor agonists or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: August 7, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • ?adrenergic agonists
    Patent number: 7241772
    Abstract: The present invention relates to 2-imidazo[1,5-a]pyridine containing ?3 adrenergic receptor agonists or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: July 10, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • ?3 adrenergic agonists
    Patent number: 7208505
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: April 24, 2007
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Rushad Eruch Karanjawala, Cynthia Darshini Jesudason, Theo Schotten, Britta Evers, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • 3-Substituted oxindole ?3 agonists
    Patent number: 7205407
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of Formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: April 17, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • Cyclopenta[b]indole derivatives as sPLAinhibitors
    Patent number: 7160909
    Abstract: A novel class of tricyclic compounds of the following formula (I) is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: January 9, 2007
    Assignee: Eli Lilly and Company
    Inventors: Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Daniel Jon Sall, Jason Scott Sawyer
  • 3-Substituted oxindole ?agonsists
    Patent number: 7122680
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: October 17, 2006
    Assignee: Eli Lilly and Company
    Inventors: Cynthia Darshini Jesudason, Daniel Jon Sall, Freddie Craig Stevens, John Arnold Werner
  • Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
    Patent number: 7115609
    Abstract: Compounds of formula (I) in which R1, R2, n and X1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: October 3, 2006
    Assignee: Eli Lilly and Company
    Inventors: Stuart Donald Jones, Daniel Jon Sall, Michael Robert Wiley
  • Cyclohept[b]indole derivatives
    Patent number: 7109231
    Abstract: A novel class of tricyclic compounds of the following formula (I): (formula I); is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: September 19, 2006
    Assignee: Eli Lilly and Company
    Inventors: Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Jr., Daniel Jon Sall, Jason Scott Sawyer
  • 3-substituted oxindole ?3 agonists
    Patent number: 7087635
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: August 8, 2006
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz, Theo Schotten, Gerd Reuhter
  • Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders
    Patent number: 7078415
    Abstract: Compounds of formula (I) in which R, R1, R2, n and X1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: July 18, 2006
    Assignee: Eli Lilly and Company
    Inventors: Michael Robert Wiley, Daniel Jon Sall, Christopher William Murray, Stephen Clinton Young, Jolie Anne Bastian
  • ?Adrenergic agonists
    Patent number: 7071208
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: July 4, 2006
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • sPLAinhibitors
    Patent number: 6992100
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, John David Jandzinski
  • sPLA2 inhibitors
    Patent number: 6974831
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 13, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith